Explore Our Blog: Expert Articles and Updates​

It’s More Common Than You Think

After giving birth, many women face physical changes they didn’t expect. One that often goes unspoken is bowel leakage, also known as fecal incontinence.

Post-traumatic stress disorder (PTSD) is a serious mental health condition that can develop after experiencing or witnessing a traumatic event. It’s estimated that about 6 in 100 adults in the U.S. will have PTSD at some point in their lives, according to the National Institute of Mental Health (NIMH).

Depression is one of the most common mental health conditions in the world and for some, finding the right treatment can be a long and difficult journey. At Segal Trials, we are actively researching new care options, including psychedelic-based approaches, to better understand how they might help people living with treatment-resistant depression.

What Is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) refers to depression that doesn’t improve after trying two or more standard antidepressant treatments. This can leave individuals feeling frustrated, hopeless, and unsure of where to turn next.

That’s where clinical research plays a vital role.

Exploring Psychedelics in Research
Psychedelics have gained attention in recent years for their potential use in mental health care. While still under investigation, certain psychedelic compounds are being studied for how they may interact with the brain differently than traditional medications.

At Segal Trials, our research team is conducting a clinical study to evaluate one of these compounds in individuals who have not responded to other treatments for depression. The goal is to learn more about its effects, safety, and potential as a new care option.

Why Participate in a Clinical Study?
By joining a clinical trial, you’re not only exploring new options for your own care — you’re helping researchers and future patients, too. Participants in our studies often receive:

• Access to care from experienced medical staff
• No-cost study-related exams and procedures
• Compensation for time and travel (if eligible)

Who Can Join?

• Our current study is enrolling adults who:
• Are between the ages of 18 and 65
• Have been diagnosed with depression
• Have not responded well to previous treatments
• Every study has specific eligibility criteria. If you’re interested, you can see if you qualify here or contact us directly.

Shaping the Future of Mental Health Care
At Segal Trials, we’ve been dedicated to advancing mental health research since 1998. With over two decades of experience and a passionate team of experts, we’re proud to support new research that could change lives.

If you or someone you know is struggling with depression and looking for new options, a research study may be a step worth exploring.

👉 Explore Current Studies

Back pain is something most people will experience at some point in their lives — but for some, it becomes a daily struggle that interferes with work, sleep, and everyday activities. It’s one of the leading causes of disability worldwide, yet many don’t fully understand what’s behind it.

Depression affects more than 264 million people worldwide. While traditional treatments like SSRIs and psychotherapy have provided relief for many, a significant portion of individuals continue to experience persistent symptoms. Recent advancements in clinical research up to 2024 have introduced innovative therapies, offering renewed hope for those with treatment-resistant depression.​

Understanding Postpartum Depression: Causes and Symptoms

Motherhood is often portrayed as a joyous and fulfilling experience, yet many new mothers face an unexpected challenge: postpartum depression (PPD). This condition can begin during pregnancy or shortly after childbirth, affecting a mother's emotional, physical, and hormonal well-being. PPD is more than just the "baby blues"; it can be a severe, long-lasting form of depression. Understanding its causes and symptoms is crucial for early intervention and support.

Bringing a new life into the world can be beautiful — but for many women, it’s also accompanied by a shadow that few talk about openly: postpartum depression. Affecting roughly 1 in 7 mothers, PPD can lead to intense sadness, anxiety, emotional numbness, and even difficulty bonding with the baby.

Post-Traumatic Stress Disorder (PTSD) affects millions of people worldwide — from combat veterans and first responders to survivors of abuse, accidents, and chronic trauma. Traditional treatments, like cognitive behavioral therapy and antidepressants, can help, but many individuals continue to suffer despite years of effort. That’s why researchers are turning to an unexpected ally: psychedelics.

Sexually transmitted infections (STIs) and mental health challenges are two of the most stigmatized health issues today — and often, they go hand in hand. The emotional weight of an STI diagnosis can lead to anxiety, depression, and social isolation. Likewise, untreated mental health struggles can increase vulnerability to risky sexual behavior. It’s a complex, often unspoken cycle — but science is stepping in with new tools, and clinical trials are at the forefront of breaking the silence.

Depression is one of the leading causes of disability worldwide, affecting more than 280 million people. Despite decades of research and the availability of antidepressants and therapy, many people still find little to no relief from conventional treatments. This growing need for alternative solutions has sparked a resurgence in one of the most intriguing — and historically controversial — areas of research: psychedelics.